Browse the evidence

Elevated tissue levels of specific ceramide species (C16:0 and C18:0) directly cause insulin resistance and metabolic dysfunction by inhibiting Akt/PKB signaling and mitochondrial efficiency.

High levels of specific fats called ceramides (C16:0 and C18:0) block your body's ability to use insulin, leading to high blood sugar and metabolic disease. While not all fats are bad, these specific ones are key drivers of insulin resistance. Managing overall metabolic health involves addressing these specific lipid accumulations, often through lifestyle changes that improve insulin sensitivity.

Increasing long-chain omega-3 intake has little or no effect on the risk of developing type 2 diabetes or on glucose metabolism markers (HbA1c, fasting glucose, insulin, HOMA-IR).

If you are taking omega-3 supplements hoping to lower your blood sugar or prevent diabetes, this review suggests you are unlikely to see those specific benefits. The evidence shows no significant change in diabetes risk or glucose levels. Continue taking them if you like for general health, but do not rely on them for diabetes management.

Transfeminine hormone therapy (estrogen + antiandrogens) induces feminizing physical changes including breast development, fat redistribution, and reduced body/facial hair, but does not significantly alter voice pitch.

Transfeminine hormone therapy will cause breast growth, fat redistribution to a female pattern, and reduced body/facial hair growth. It will NOT significantly lower your voice pitch. If voice pitch change is a priority, you will likely need voice training or surgery in addition to hormones. Breast development varies, with many reaching a plateau at a smaller cup size (AAA or less) within 6 months.

Weekly oral fecal microbiota transplantation (FMT) from lean donors does not significantly improve insulin sensitivity, body weight, or body composition in adults with obesity and mild-to-moderate insulin resistance over a 12-week period.

For adults with obesity and mild insulin resistance, receiving weekly oral FMT capsules from lean donors does not significantly improve insulin sensitivity, weight, or body composition over 12 weeks. While the treatment is safe and alters gut bacteria, it should not be expected to replace lifestyle interventions like diet and exercise for metabolic improvement.

Genetic factors, particularly polymorphisms affecting neurotransmitter systems (dopamine, serotonin) and metabolic traits (BMI, insulin resistance), significantly increase the risk of developing eating disorders, with distinct genetic architectures for anorexia nervosa versus binge-type disorders.

If you have a family history of eating disorders, you may have a biological predisposition. This is not your fault, but it is a risk factor you can manage. Focus on early identification of symptoms and seek professional support if you notice changes in eating habits or body image, as genetic risk can be mitigated by environmental factors.

Childhood trauma, abuse, and neglect are strongly linked to the development of eating disorders, particularly Bulimia Nervosa and Binge Eating Disorder, through interactions with genetic susceptibility.

If you have experienced childhood trauma, you may be at higher risk for eating disorders. This risk is not inevitable, but it is significant. Trauma-informed therapy and support can help address the underlying emotional pain that may manifest as disordered eating.

Pharmacological inhibition of BCKDK using BT2 reduces plasma branched-chain amino acid (BCAA) and branched-chain alpha-keto acid (BCKA) levels, thereby attenuating obesity-associated insulin resistance in obese mice.

In obese individuals, high levels of branched-chain amino acids (BCAAs) and their metabolites contribute to insulin resistance. This study suggests that enhancing the body's ability to break down BCAAs (via BCKDK inhibition) improves insulin sensitivity. While BT2 is a drug, the findings support the idea that managing BCAA metabolism is key to treating obesity-related metabolic issues.

Elevated levels of branched-chain alpha-keto acids (BCKAs) impair insulin signaling by activating mTORC1, independent of BCAAs.

BCKAs, metabolites of BCAAs, directly impair insulin signaling by activating mTORC1. This suggests that managing BCAA metabolism is crucial for preventing insulin resistance, as BCKAs are not just inert byproducts but active contributors to metabolic dysfunction.

Chronic tissue inflammation, driven by obesity-induced macrophage accumulation and proinflammatory cytokine release, is a major etiologic cause of insulin resistance and beta-cell dysfunction in metabolic disease.

In obesity, fat tissue doesn't just store energy; it becomes inflamed, releasing chemicals that block insulin from working properly in your muscles, liver, and pancreas. This inflammation is a direct cause of Type 2 Diabetes risk. Managing metabolic health requires addressing this underlying inflammatory state, not just caloric intake.

Chronic inflammation in pancreatic islets, driven by macrophage infiltration and proinflammatory cytokines (IL-1β, IL-23, IL-24), causes beta-cell dysfunction and reduced glucose-stimulated insulin secretion (GSIS) in Type 2 Diabetes.

In Type 2 Diabetes, inflammation inside the pancreas damages the insulin-producing beta cells. This isn't just about insulin resistance; the pancreas itself gets inflamed, reducing its ability to secrete insulin when needed. Protecting beta cells from inflammation is a key therapeutic target.

Growth Hormone (GH) injections do not increase muscle strength in sarcopenic patients and are associated with frequent side effects.

Do not use Growth Hormone injections to treat sarcopenia. They do not improve strength and cause side effects. Focus on exercise instead.

Advanced paternal age is associated with decreased sperm parameters (except concentration), increased DNA fragmentation, and higher risk of genetic disorders in offspring.

As men age, sperm quality declines, DNA fragmentation increases, and the risk of genetic disorders in children rises. Couples with advanced paternal age should be counseled cautiously regarding ART success rates and potential genetic risks.

Standard diagnostic tests (fasting glucose, HbA1c, OGTT) fail to identify glucose dysregulation in a significant subset of individuals classified as normoglycemic, who exhibit severe postprandial glucose variability and spikes into prediabetic/diabetic ranges when monitored via continuous glucose monitoring (CGM).

Standard blood tests (A1C, fasting glucose) can miss hidden glucose spikes. If you are 'normal' on labs but have risk factors, consider Continuous Glucose Monitoring (CGM) or standardized meal challenges to see how your body actually responds to food. This can reveal 'severe glucotypes' that indicate higher risk for diabetes and heart disease despite normal static labs.

Neck circumference (NC) is uniquely associated with the prevalence of common carotid artery (CCA) plaque in diabetic adults, independent of other abdominal obesity indices.

Measuring neck circumference is a simple, low-cost screening tool for diabetic patients to assess the risk of carotid artery plaque. Clinicians should incorporate NC measurements into routine diabetes care to identify patients at higher risk for vascular complications, especially since it provides unique information not captured by waist circumference or BMI.

Chronic hyperglycemia induces oxidative stress via multiple metabolic pathways (polyol, AGE, PKC, hexosamine), which directly causes insulin resistance and beta-cell dysfunction, leading to Type 2 Diabetes.

Managing blood sugar levels is critical not just for immediate comfort, but to prevent the cellular oxidative stress that drives long-term complications like nerve and kidney damage. Focus on dietary strategies that minimize glucose spikes to reduce the metabolic burden on your cells.

Despite high rates of medical treatment (89.1% of diagnosed diabetics), glycemic control remains poor, with only 23.3% achieving the target HbA1c <6.5% and 43.5% achieving <7.0%.

Just because you are taking diabetes medication doesn't mean your blood sugar is under control. Only about 1 in 4 people achieve the strict target of HbA1c <6.5%. You need to check your HbA1c regularly to ensure your treatment plan is actually working.

In obesity, chronic low-grade inflammation in brown and beige adipose tissue impairs thermogenic activity and glucose uptake, contributing to metabolic syndrome.

Obesity triggers inflammation in fat tissue that shuts down its ability to burn energy and process sugar. This isn't just about calories in vs. out; it's about the tissue's health. Reducing inflammation through healthy lifestyle choices may help restore the function of brown and beige fat, improving metabolic flexibility.

Pro-inflammatory cytokines, particularly TNFα, impair brown adipose tissue thermogenesis by reducing UCP1 expression and insulin sensitivity.

High levels of inflammatory markers in the body can directly interfere with your brown fat's ability to burn calories and process glucose. Managing systemic inflammation is key to maintaining metabolic health.

Inflammation in perivascular adipose tissue (PVAT) and epicardial adipose tissue (eAT) promotes cardiovascular damage by releasing pro-inflammatory signals and reducing vasoprotective brown adipokines.

Fat stored around your heart and blood vessels isn't just inert storage; it actively communicates with your cardiovascular system. Inflammation in this fat can damage blood vessels and increase heart disease risk. Reducing overall body fat and inflammation may protect your heart.

Obesity-associated cardiovascular risk is driven by adipose tissue dysfunction and altered adipokine secretion (specifically increased leptin/resistin and decreased adiponectin/omentin-1), rather than body mass index (BMI) alone.

If you have obesity, your risk for heart disease is heavily influenced by the hormones your fat cells release, not just your weight. Visceral fat is particularly harmful because it releases pro-inflammatory signals (like leptin and resistin) and fewer protective signals (like adiponectin). While weight loss helps, interventions that improve metabolic health (like bariatric surgery) work partly by restoring this hormonal balance, not just by reducing mass.

Leptin resistance in obesity reverses its protective vascular effects, contributing to a pro-oxidative state, endothelial dysfunction, and accelerated biological senescence.

In obesity, high leptin levels do not protect the heart because the body becomes resistant to them. This resistance allows leptin to promote oxidative stress and endothelial dysfunction, increasing cardiovascular risk. Restoring leptin sensitivity (e.g., through weight loss or bariatric surgery) may help restore these protective vascular effects.

Bariatric surgery improves cardiovascular risk profiles by significantly altering adipokine secretion profiles, specifically decreasing leptin and increasing adiponectin, independent of simple caloric restriction.

Bariatric surgery is effective not just because it reduces stomach size, but because it fundamentally changes the hormones your fat cells release. It lowers leptin (reducing resistance) and raises adiponectin (improving insulin sensitivity and reducing inflammation), which collectively improve cardiovascular risk.

Intermittent hypoxia (IH) characteristic of obstructive sleep apnea causes hypertension by dysregulating Hypoxia-Inducible Factors (HIF-1α and HIF-2α), which increases reactive oxygen species (ROS) to activate the sympathetic nervous system and impair baroreflex function.

If you have sleep apnea, the repeated drops in oxygen during sleep trigger a chemical response (HIF/ROS) that keeps your nervous system in 'fight or flight' mode, raising blood pressure even when you are awake. Treating the apnea (e.g., with CPAP) is critical, but because this chemical signaling can persist or cause vascular remodeling, blood pressure may not return to normal without additional targeted interventions. Managing OSA is not just about breathing; it is about stopping the chemical signal that drives hypertension.

Intermittent hypoxia causes insulin resistance and Type 2 Diabetes by increasing ROS in pancreatic beta cells via HIF-1α, leading to hypersecretion of insulin and eventual beta-cell dysfunction.

Sleep apnea doesn't just affect your heart; it stresses your pancreas. The repeated oxygen drops trigger a response (HIF-1/ROS) that forces your beta cells to overwork and secrete too much insulin, leading to insulin resistance and Type 2 Diabetes. Treating your sleep apnea is essential to protect your metabolic health, not just your blood pressure.